Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual DiseaseTalha Munir, Peter Hillmen, David Allsup et al.|New England Journal of Medicine|2023Cited by 155
Measurable Residual Disease–Guided Therapy for Chronic Lymphocytic LeukemiaTalha Munir, Peter Hillmen, Andy C. Rawstron et al.|New England Journal of Medicine|2025Cited by 26
Acquired Bruton's tyrosine kinase mutations in patients treated on the ibrutinib and rituximab, ibrutinib alone, and ibrutinib and venetoclax arms of the national multi-centre Phase III FLAIR study in previously untreated CLL patientsCharlotte Evans, Talha Munir, Andy C. Rawstron et al.|Blood|2025Cited by 2
Additional file 1: of Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trialLaura Collett, Peter Hillmen, Claire Hulme et al.|Figshare|2017Cited by 0
Additional file 1: of Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trialDena Howard, Peter Hillmen, Talha Munir et al.|Figshare|2016Cited by 0